Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Background: Seasonal allergic rhinoconjunctivitis or hay fever is caused due to the sensitization to pollen allergens, usually from grasses. Lolium multiflorum (Lm) is one of the most important grass pollen allergens in Southern Brazil. Objectives: To evaluate three different pollen extraction methods and to analyze IgE, IgG1 and IgG4 responses to Lm pollen antigens in pollinosis patients. Methods: Three different Lm pollen extracts were prepared (LmPBS extract, Lme-PBS extract and LmNH4HCO3 extract) and analyzed in 13.5% SDS-PAGE. Serum samples from 62 patients with seasonal allergic rhinoconjunctivitis and/or asthma (Lm+ group), 30 patients with perennial allergy rhinitis (Lm- group) and 30 non-atopic subjects (NA) were tested for IgE reactivity to three Lm extracts by ELISA. Lm-specific IgG1 and IgG4 antibodies were also evaluated by using LmPBS extract only in ELISA. Results: By SDS-PAGE, the three extracts were very similar, showing bands ranging from 20 to 100 kDa. By ELISA-IgE, the results revealed higher IgE levels in pollinosis patients when LmPBS extract was used. LmPBS extract was chosen to evaluate the IgE, IgG1 and IgG4 responses and their levels were higher in the Lm+ patients when compared to Lm and NA groups. In the Lm+ group, IgE (EI = 17.6) levels were higher than IgG1 (EI = 2.6) and IgG4 (EI = 3.6) levels, while in other groups there were not any differences in the antibody levels. Conclusions: LmPBS extract was effective in detecting IgE, IgG1 and IgG4 responses to Lolium multiflorum pollen antigens. These antibody classes are in a higher level in pollinosis patients when compared to non-sensitized subjects. Lm allergen extracts for in vivo and in vitro using should be standardized. / Introdução: A rinite alérgica estacional ou doença polínica se deve à sensibilização aos alérgenos de pólens, geralmente de gramíneas. Lolium multiflorum (Lm) é uma gramínea com pólens de elevado potencial alergênico, sendo a principal gramínea causadora de polinose na região Sul do Brasil. Objetivos: Analisar três diferentes métodos de extração antigênica pela reatividade IgE de cada extrato e as respostas anticórpicas IgE, IgG1 e IgG4 específicas aos antígenos de pólen de Lm. Material e Métodos: Três extratos de pólen de Lm foram preparados (extratos LmPBS, Lme- PBS e LmNH4HCO3) e analisados por SDS-PAGE a 13,5%. Amostras de soro de 62 pacientes com rinite alérgica sazonal e/ou asma brônquica (grupo Lm+), 30 pacientes com rinite alérgica perene (grupo Lm-) e 30 indivíduos não-atópicos (grupo NA) foram testadas para a reatividade IgE frente aos três extratos por ELISA. Anticorpos IgG1 e IgG4 específicos a Lm foram avaliados empregando-se somente o extrato LmPBS, por ELISA. Resultados: O perfil protéico dos extratos foi muito semelhante por SDS-PAGE, apresentando bandas protéicas de 20 a100 kDa. Níveis de IgE foram maiores em pacientes com polinose ao se utilizar o extrato LmPBS. O extrato LmPBS foi utilizado para avaliar os níveis de IgE, IgG1 e IgG4, que foram maiores nos pacientes com polinose que em pacientes Lm- e indivíduos NA. No grupo Lm+, os níveis médios de IgE (IE = 17,6) foram maiores que os níveis de IgG1 (IE = 2,6) e IgG4 (IE = 3,6) (p < 0,001). Conclusões: O extrato LmPBS foi eficiente em detectar as respostas IgE, IgG1 e IgG4 a antígenos de pólen de Lm. Essas classes de anticorpos estão em níveis maiores em pacientes com polinose. Extratos antigênicos de Lm para uso in vivo e in vitro devem ser padronizados. / Mestre em Imunologia e Parasitologia Aplicadas

Affinity proteins are invaluable tools in biotechnological and medical applications. This thesis is about combinatorial protein engineering principles for the generation of novel affinity proteins to purify mouse immunoglobulin, detect a potential cancer marker protein or inhibit a cell proliferation pathway. In a first study, ribosome display was for the first time applied to the selection of so-called affibody molecules, including the design of a ribosome display gene cassette, initial test enrichment experiments and the selection of binders against murine IgG1. One of the selected binders (ZMAB25) showed a highly selective binding profile to murine IgG1, which was exploited in the recovery of two different mouse monoclonal IgG1 antibodies from a bovine immunoglobulin-containing background. Ribosome display was further applied to the selection of affibody molecules binding to SATB1, a suggested marker protein for metastasizing adenocarcinoma. The study also included the selection of VHH antibody fragments from a naïve gene repertoire displayed on phage. Binders from both classes of protein scaffolds could be isolated that selectively recognized SATB1 but not its close homologue SATB2, and were used to detect endogenous SATB1 in Jurkat cells by immunofluorescence microscopy. The well-established phage display technology was used to select affibody molecules binding to H-Ras and Raf-1, both involved in the mitogen-activated protein kinase (MAPK) pathway and playing a central role in the control of cell proliferation, survival and differentiation. An isolated affibody molecule denoted ZRAF322 was found to selectively bind to Raf-1 and inhibit the interaction between H-Ras and Raf-1 in vitro. In a continued effort, ribosome display was applied to the affinity maturation of the ZRAF322 variant in a novel approach, based on repetitive cycles of diversification by error-prone PCR of the entire affibody gene and ribosome display selection, mimicking the principles of natural evolution. The method involved a monitoring of the progress of evolution and variants of ZRAF322 with 13- to 26-fold improved affinities were obtained, that contained different combinations of single or double amino acid substitutions in either previously randomized or framework positions. Implications of the substitutions for binder stability and selectivity were also investigated, showing that a higher affinity could be associated with a lower thermal melting point and that affinity-improved variants showed uncompromised binding selectivity to the hRaf-1 target. / QC 20110506

This study aimed to evaluate the clinical efficacy and systemic/mucosal antibody response changes after sublingual immunotherapy (SLIT) using Dermatophagoides pteronyssinus (Dpt) allergens with or without bacterial extracts in mite-allergic children. One-hundred and two patients presenting allergic rhinitis with or without asthma were selected for a randomized double-blind, placebo-controlled trial and distributed into three groups: DPT (Dpt allergen extract, n=34), DPT+MRB (Dpt allergen plus mixed respiratory bacterial extracts, n=36), and Placebo (n=32). Clinical evaluation and immunological analyses were carried out before and after 12 and 18 months of treatment, including rhinitis/asthma symptom and medication scores, skin prick test (SPT) to Dpt extract, and measurements of Dpt, Der p 1, Der p 2 specific IgE, IgG4, and IgG1 in serum and specific IgA in saliva and nasal lavage fluid. Clinical results showed a significant decline in rhinitis/asthma symptom scores in all groups, but medication use decreased only in DPT group after 12 months. SPT results showed no significant changes and SLIT was generally safe, with no severe systemic reactions. SLIT using Dpt allergen alone induced increased serum IgG4 levels to Dpt, Der p 1 and Der p 2, and increased serum IgG1 and salivary IgA levels to Dpt and Der p 1. SLIT using DPT+MRB was able to decrease IgE levels to Der p 2, to increase salivary IgA levels to Der p 1, but had no changes on specific IgG4 and IgG1 levels. In conclusion, clinical improvement was observed both in the SLIT group and the control, but only active SLIT was able to modulate the mucosal/systemic antibody responses. These findings support the role of specific serum IgG4 and IgG1, in addition to salivary IgA, as probable blocking antibodies or biomarkers of tolerance that may be useful for monitoring the allergen specific immunotherapy. / Este estudo teve como objetivo avaliar a eficácia clínica e alterações da resposta de anticorpos sistêmicos e de mucosa após a imunoterapia sublingual (SLIT), utilizando alérgenos de Dermatophagoides pteronyssinus (Dpt), com ou sem extratos bacterianos em crianças alérgicas a ácaros. Cento e dois pacientes com rinite alérgica com ou sem asma foram selecionados para um estudo randomizado duplocego, controlado por placebo e distribuídos em três grupos: DPT (extrato alergênico de Dpt, n=34), DPT+MRB (extrato alergênico de Dpt associado com extrato de bactérias mistas do trato respiratório, n=36), e Placebo (n=32). Avaliação clínica e análises imunológicas foram realizadas antes do tratamento e após 12 e 18 meses, incluindo a pontuação de escores de sintomas e medicamentos de rinite/asma, teste cutâneo (SPT) ao extrato Dpt, e medidas de anticorpos específicos IgE, IgG4 e IgG1 para Dpt, Der p 1, Der p 2 no soro e IgA específicos na saliva e no lavado nasal. Os resultados clínicos mostraram uma redução significativa nos escores de sintomas de rinite/asma em todos os grupos, mas o uso de medicamentos diminuiu apenas no grupo DPT após 12 meses. Resultados de SPT não mostraram mudanças significativas e SLIT foi geralmente segura, sem reação sistêmica grave. SLIT usando somente alérgeno Dpt induziu aumento dos níveis de IgG4 para Dpt, Der p 1 e Der p 2 no soro, e aumentou os níveis de IgG1 no soro e salivares de IgA para Dpt e Der p 1. SLIT usando DPT+MRB foi capaz de diminuir os níveis de IgE para Der p 2, aumentar os níveis salivares de IgA para Der p 1, mas não tiveram alterações nos níveis de anticorpos específicos de IgG4 e IgG1. Em conclusão, foi observado melhora clínica tanto no grupo da SLIT como do controle, porém somente na SLIT com alérgeno foi capaz de modular as respostas de anticorpos sistêmicos e de mucosa. Estes achados reforçam o papel de anticorpos IgG4 e IgG1 séricos específicos, além de IgA salivar, como prováveis anticorpos bloqueadores ou biomarcadores de tolerância que podem ser úteis para monitoramento da imunoterapia alérgeno-específica. / Doutor em Imunologia e Parasitologia Aplicadas

<p>Monoclonal antibodies (mAbs) as therapeutic proteins have shown great potential in treatment of various human diseases because of their highly specific nature. This has attracted worldwide attention leading to increased demand for such mAb products. To meet this demand large scale manufacturing is carried out using recombinant mammalian cell culture techniques for high yields and faster production. mAb products are worth the investment if produced in their native state. The quantity of mAb present in such cell cultures is very less and therefore special care is needed while handling them. Purifying antibody molecules from heterogeneous cell culture impurities and maintaining their native functional state is a critical task mainly because these antibodies are labile in nature. Care also need to be exercised during processing because mAbs have inherent tendancy to aggregate which is undesirable since such aggregates in antibody formulation produces immunogenic reaction when injected in humans. The other important factor in mAb purification is the processing cost involved since majority of the total production cost is utilized for purification of mAb. Protein-A chromatography is the first choice for purifying antibodies and is widely adopted. However failure in distinguishing between monomer and aggregate antibody molecules along with harsh acidic processing conditions necessitates the use of further purification steps.</p> <p>In this work various techniques for mAb processing are discussed and are outlined below:</p> <p>Removal of impurities from mAbs is a major challenge and this thesis discusses various processing options available to purify these mAbs. Impurities in mAb products are usually the aggregate byproducts formed due to unfolded monomer antibody molecules. These molecules are naturally hydrophobic in nature and display great differences in hydrophobicity on aggregation. Hydrophobic interaction membrane chromatography (HIMC) makes use of this hydrophobicity difference and helps in removal of aggregate impurities from monomer antibody.</p> <p>Heavy chain mAbs (hcmAbs) are promising new developments in the area of biopharmaceuticals because of their unique structural composition. Similar to conventional mAbs these hcmAbs are also rapidly finding their way into therapeutic markets. Purifying hcmAbs will be an important step in their development and for this purpose we use HIMC technique for removing impurities and obtain pure product.</p> <p>Antibody molecules are almost always lost as aggregates which leads to great economic losses and the ability to disaggregate these mAb oligomers would be of significant practical and scientific interest. In this work a novel thermalcycling technique is discussed to disaggregate such mAb oligomers and potentially recover functional monomer mAb molecules.</p> / Master of Applied Science (MASc)